Amfepramone, also known asdiethylpropion, is a medication used in the short-term management ofobesity.[2] It is used together with diet and exercise.[2] Use is not recommended beyond a few weeks.[2]
Amfepramone is most closely chemically related to the antidepressant andsmoking cessation aidbupropion (previously called amfebutamone), which has also been developed as a weight-loss medicine when in a combination product withnaltrexone.[11]
Society and culture
Names
Another medically-utilized name is diethylpropion (BAN andAAN). Chemical names include: α-methyl-β-keto-N,N-diethylphenethylamine,N,N-diethyl-β-ketoamphetamine andN,N-diethylcathinone.Brand names include: Anorex, Linea, Nobesine, Prefamone, Regenon, Tepanil and Tenuate.
Legality
Amfepramone is classified as aSchedule IVcontrolled substance in the United States. It is also a Schedule IV controlled substance in Canada. In the UK amfepramone is a class C drug[12] and as a medicine, it is a Schedule 3 Controlled Drug which requires safe custody.
Recreational use
The authors of several studies of amfepramone claim that the substance has a relatively low potential for causing addiction in users.[13][14][15][16] However, there have been reports of people using this drug recreationally in the UK. Recreational users of amfepramone in the UK refer to amfepramone tablets as "tombstones".
↑1.01.11.21.31.41.51.6"Diethylpropion".LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012.Archived from the original on 6 May 2021. Retrieved24 December 2021.Archived 6 May 2021 at theWayback Machine
↑Hyde JF, Browning E, Adams R (1928). "Synthetic Homologs of d,l-Ephedrine".Journal of the American Chemical Society.50 (8):2287–2292.doi:10.1021/ja01395a032.
↑Arias HR, Santamaría A, Ali SF (2009). "Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion".New Concepts of Psychostimulant Induced Neurotoxicity. International Review of Neurobiology. Vol. 88. pp. 223–55.doi:10.1016/S0074-7742(09)88009-4.ISBN9780123745040.PMID19897080.
↑Jasinski DR, Krishnan S (June 2009). "Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse".Journal of Psychopharmacology.23 (4):419–27.doi:10.1177/0269881109103113.PMID19329547.S2CID6138292.
